Nemonapride (Emilace) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. Nemonapride acts as a D2 and D3 receptor antagonist and is also a potent 5-HT1A receptor agonist. It has affinity for sigma receptors.
This page contains content from the copyrighted Wikipedia article "Nemonapride"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
